Oral delivery of peptide therapeutics remains challenging due to gastrointestinal (GI) degradation and poor intestinal absorption. Here, we propose a self-immolative peptide prodrug conjugate (SIPPC) platform for inflammation-targeted oral delivery, integrating a hydrophilic polyethylene glycol segment, a reactive oxygen species (ROS)–responsive hydrophobic self-immolative module, and a hydrolyzable scaffold, which collectively enable spontaneous assembly into micelle-like nanoparticles. Using three anti-inflammatory peptides (KPV, Ac-QAW, and IRW), we demonstrated that the engineered conjugates exhibit remarkable GI stability, efficient mucus penetration, and ROS-responsive release at inflamed sites. In colitis mice, the KPV-based conjugate (proKPV) achieved a 3.8-fold greater colonic accumulation than free KPV, with enhanced efficacy even at a 20-fold lower dose. Beyond therapeutic effects in the colitis model, oral proKPV substantially accumulated in inflamed lungs and exhibited potent anti-inflammatory efficacy in mice with acute lung injury. Ac-QAW and IRW-based conjugates exhibited comparable benefits, underscoring SIPPC as a transformative paradigm for oral peptide therapeutics, offering substantial promise for clinical translation in inflammatory disorders.

2025-10-01·International Journal of Medical Sciences

Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review

Review

作者: Maarof, Manira ; Fauzi, Mh Busra ; Fadilah, Nur Izzah Md ; Adnan, Siti Balqis

Wound healing is a complex and dynamic process that requires the coordination of cellular, molecular, and physiological events to restore tissue integrity. Despite notable advances in treatment strategies, optimizing healing outcomes, particularly in chronic wounds, remains a major challenge. Emerging evidence highlights the therapeutic promise of peptides, especially tripeptides, in accelerating tissue repair through diverse mechanisms. These short peptides regulate key processes such as cell migration, proliferation, and differentiation, while also modulating inflammation, promoting angiogenesis, and facilitating extracellular matrix (ECM) remodeling. This review, covering studies published between 2016 and 2025, explores the role of tripeptides in enhancing wound repair, emphasizing their biological functions, mechanisms of action, and therapeutic applications. Recent findings demonstrate that tripeptides can stimulate fibroblast migration, enhance collagen deposition, and support angiogenesis. In addition, they exhibit antimicrobial and anti-inflammatory properties, making them valuable candidates for both acute and chronic wound management. GHK-based formulations, including nanoparticle conjugates, hydrogels, and clinical derivatives such as TriHex and TriHex 2.0, enhance fibroblast migration, ECM remodeling, collagen and elastin synthesis, and wound closure while providing antimicrobial activity. KdPT mitigates hyperglycemia-induced oxidative stress and restores keratinocyte function, whereas KPV-loaded hydrogels reduce inflammation, promote tissue regeneration, and combat MRSA infections. Additionally, lipotripeptides (DICAMs) inhibit and disrupt bacterial biofilms, and GPE supports neuroprotection and regeneration through ERK and PI3K/Akt signaling activation. Beyond wound repair, this review also discusses comparative physicochemical properties and wound healing applications of tripeptides versus larger peptides, factors influencing their performance, strategies for combination with biomaterial scaffolds, and emerging applications in fields such as cancer and cosmetics. Collectively, tripeptides represent a promising class of multifunctional bioactive molecules in wound care, offering novel avenues for targeted tissue regeneration. Future research should focus on improving their stability, bioavailability, and delivery systems to fully harness their clinical potential in regenerative medicine.

2024-12-01·Advanced Healthcare Materials

KPV and RAPA Self‐Assembled into Carrier‐Free Nanodrugs for Vascular Calcification Therapy

Article

作者: Jiang, Longqi ; Zhang, Jie ; Zhang, Li ; Liu, Zhenyu ; Aierken, Yierpani ; Lin, Zipeng ; Li, Qingzhu ; Wu, Ya ; Liu, Yong ; Li, Dongze

Abstract:

Cardiovascular disease (CVD) is a leading cause of death globally, and vascular calcification (VC) is an important independent risk factor for predicting CVD. Currently, there are no established therapeutic strategies for the treatment of VC. Although recognized combination therapies of nanomedicines can provide effective strategies for disease treatment, the clinical application of nanomedicines is limited because of their complex preparation processes, low drug loading rates, and unpredictable safety risks. Thus, developing a simple, efficient, and safe nanodrug to simultaneously regulate inflammation and autophagy may be a promising strategy for treating VC. Herein, an anti‐inflammatory peptide (lysine‐proline‐valine peptides, KPV) and the autophagy activator rapamycin (RAPA) are self‐assembled to form new carrier‐free spherical nanoparticles (NPs), which shows good stability and biosafety. In vivo and in vitro, KPV‐RAPA NPs significantly inhibit VC in mice compared to the other treatment groups. Mechanistically, KPV‐RAPA NPs inhibit inflammatory responses and activated autophagy. Therefore, this study indicates that the new carrier‐free KPV‐RAPA NPs have great potential as therapeutic agents for VC combination therapy, which can promote the development of nanodrugs for VC.

项与 KPV 相关的新闻（医药）

2026-01-09

·EINPresswire

Javelin Sciences Adds the World’s First Topical KLOW80 Peptide Formula to Research Offerings

BURTON, MI, UNITED STATES, January 9, 2026 / EINPresswire.com / -- Javelin Sciences , a CLIA-certified biotechnology leader in advanced diagnostics and custom peptide engineering, today unveiled the world’s first topical formulation of the KLOW80 peptide blend, now available exclusively to qualified physicians and researchers for laboratory and investigative use. The innovative KLOW80 Topical Formula combines four extensively studied regenerative peptides—GHK-Cu (copper tripeptide-1), BPC-157, TB-500 (Thymosin Beta-4 fragment), and KPV—in a stable, transdermal delivery system designed for non-invasive application in controlled research settings. This marks the first time this synergistic multi-peptide blend, widely researched for its potential in tissue repair, inflammation modulation, collagen synthesis, and wound healing, has been adapted into a topical format suitable for dermal and localized studies. Traditional research with KLOW80 has relied on injectable or systemic administration, limiting investigations into direct topical effects on skin, epithelial tissues, and localized injury models. Javelin Sciences’ breakthrough formulation overcomes these barriers with enhanced bioavailability, precise dosing, and a non-greasy, research-grade vehicle optimized for stability. “This topical KLOW80 represents a significant advancement for regenerative peptide research,” said Alan Morrison, Founder and CEO of Javelin Sciences. “By enabling targeted, non-systemic delivery, researchers and physicians can now explore localized mechanisms of action—such as accelerated wound closure, reduced scarring, improved skin barrier function, and anti-inflammatory responses—in ways previously unavailable. We’re proud to pioneer this format while maintaining the highest standards of purity and scientific rigor.” Key features of the KLOW80 Topical Formula include: Synergistic blend of GHK-Cu (primary component), BPC-157, TB-500, and KPV at research-optimized concentrations Pharmaceutical-grade transdermal base for controlled absorption studies Stringent third-party testing for purity, potency, and stability Available in metered-dose packaging for reproducible experimental application The product is strictly for research use only and is restricted to licensed physicians, academic institutions, and qualified research facilities. It is not intended for human cosmetic or therapeutic application. This launch builds on Javelin Sciences’ recent milestone as the first U.S. lab to offer direct SARS-CoV-2 spike protein testing and reinforces the company’s commitment to innovative, peer-reviewed tools for clinical and defense research. For ordering information or qualification inquiries, visit www.javelinsciences.com or contact info@javelinsciences.com. About Javelin Sciences Javelin Sciences specializes in precision peptide engineering, advanced diagnostic testing, and secure biotech consulting for clinical, research, and defense partners. All products and services adhere to strict quality and regulatory standards. Brent Hale Javelin Sciences b.hale@javelinsciences.com Visit us on social media: Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.